Jardiance

DRUG4 trials

Sponsors

Boehringer Ingelheim, University of Louisville, Baylor Research Institute

Conditions

AtherosclerosisChronic Kidney DiseaseCoronary Artery DiseaseDiabetes Mellitus, Type 2Heart AttackHeart Failure of Reduced Ejection Fraction (HFrEF)Type 2 Diabetes

Phase 4

Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)

WithdrawnNCT06280976

University of LouisvilleAtherosclerosis, Coronary Artery Disease, Heart Attack

Start: 2024-03-01End: 2025-01-01Updated: 2025-03-17

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

Enrolling by invitationNCT07547878

Baylor Research InstituteChronic Kidney Disease, Type 2 Diabetes

Start: 2026-04-08End: 2029-03-31Target: 64Updated: 2026-10-13

Unknown Phase

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

CompletedNCT02489942

Boehringer IngelheimDiabetes Mellitus, Type 2

Start: 2015-06-12End: 2020-12-04Updated: 2022-02-04

Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction

Not yet recruitingNCT07044700

Boehringer IngelheimHeart Failure of Reduced Ejection Fraction (HFrEF)

Start: 2028-01-31End: 2028-12-31Target: 5000Updated: 2026-09-15

Related Papers

Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study

Expert Opinion on Drug Safety2019-11-2627 citations